Dynamic Monitoring of Circulating Tumor DNA to Predict Prognosis and Efficacy of Adjuvant Chemotherapy after Resection of Colorectal Liver Metastases
10.7150/thno.59644 · doi-reference
Dynamic Changes in Longitudinal Circulating Tumour DNA Profile during Metastatic Colorectal Cancer Treatment
10.1038/s41416-022-01837-z · doi-reference
Immune Checkpoint Inhibitors for POLE or POLD1 Proofreading‐Deficient Metastatic Colorectal Cancer
10.1016/j.annonc.2024.03.009 · doi-reference
Tumour Mutational Burden as a Biomarker in Patients with Mismatch Repair Deficient/Microsatellite Instability‐High Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
10.1016/j.ejca.2023.03.029 · doi-reference
Tumor Mutational Burden in Colorectal Cancer: Implications for Treatment
10.1016/j.critrevonc.2024.104342 · doi-reference
Liver Metastases Dampen IL18‐Driven Γδ T Cell Activity and Immunotherapy Responsiveness in Colorectal Cancer
10.1016/j.xcrm.2025.102579 · doi-reference
Pembrolizumab Versus Chemotherapy in Microsatellite Instability‐High or Mismatch Repair‐Deficient Metastatic Colorectal Cancer: 5‐Year Follow‐Up from the Randomized Phase III KEYNOTE‐177 Study
10.1016/j.annonc.2024.11.012 · doi-reference
Tumour‐Agnostic Circulating Tumour DNA Analysis for Improved Recurrence Surveillance after Resection of Colorectal Liver Metastases: a Prospective Cohort Study
10.1016/j.ejca.2021.12.026 · doi-reference
Postoperative Circulating Tumour DNA Is Associated with Pathologic Response and Recurrence‐Free Survival After Resection of Colorectal Cancer Liver Metastases
10.1016/j.ebiom.2021.103498 · doi-reference
Circulating Tumor DNA Dynamics and Recurrence Risk in Patients Undergoing Curative Intent Resection of Colorectal Cancer Liver Metastases: A Prospective Cohort Study
10.1371/journal.pmed.1003620 · doi-reference
Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver Metastases: A Multicenter Cohort Study
10.1093/gastro/goaf098 · doi-reference
Effect of KRAS Mutation on Long‐Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases
10.1245/s10434-015-4587-z · doi-reference
The Role of Circulating Biomarkers in the Early Detection of Recurrent Colorectal Cancer Following Resection of Liver Metastases
10.31083/j.fbl2706189 · doi-reference
The Combined Detection of Carcinoembryonic Antigen, Carcinogenic Antigen 125, and Carcinogenic Antigen 19‐9 in Colorectal Cancer Patients
10.4240/wjgs.v16.i7.2073 · doi-reference
Use of Dynamic Contrast‐Enhanced Magnetic Resonance Imaging Combined With Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19‐9 in Predicting Colorectal Cancer Liver Metastasis
10.1002/jcu.23917 · doi-reference
Clinical Usefulness of Postoperative Serum Carcinoembryonic Antigen in Patients with Colorectal Cancer with Liver Metastases
10.1245/s10434-022-12301-w · doi-reference
Meta‐Analysis of the Prognostic Value of Serum Carcinoembryonic Antigen in Patients with Colorectal Cancer Liver Metastases after Hepatectomy
10.1097/cej.0000000000000859 · doi-reference
Prognostic Role of Serum Carcinoembryonic Antigen in Patients Receiving Liver Resection for Colorectal Cancer Liver Metastasis: A Meta‐analysis
10.4240/wjgs.v15.i12.2890 · doi-reference
Exosomal circPABPC1 Promotes Colorectal Cancer Liver Metastases by Regulating HMGA2 in the Nucleus and BMP4/ADAM19 in the Cytoplasm
10.1038/s41420-022-01124-z · doi-reference
Identification of Biomarkers Associated with Liver Metastasis Progression from Colorectal Cancer Using Exosomal RNA Profiling
10.3390/cancers14194723 · doi-reference
Seed and Soil: Consensus Molecular Subgroups (CMS) and Tumor Microenvironment Features Between Primary Lesions and Metastases of Different Organ Sites in Colorectal Cancer
10.2147/cmar.s441675 · doi-reference
Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer
10.1001/jamasurg.2018.0996 · doi-reference
Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta‐Analysis
10.1016/j.clcc.2017.01.004 · doi-reference
A Systematic Literature Review and Meta‐Analysis Describing the Prevalence of KRAS, NRAS, and BRAF Gene Mutations in Metastatic Colorectal Cancer
10.14740/gr1167 · doi-reference
Highly Efficient PD‐1‐Targeted CRISPR‐Cas9 for Tumor‐Infiltrating Lymphocyte‐based Adoptive T Cell Therapy
10.1016/j.omto.2022.01.004 · doi-reference
Generation of Colon Cancer‐Derived Tumor‐Infiltrating T Cells (TILs) for Adoptive Cell Therapy
10.1016/j.jcyt.2023.01.009 · doi-reference
Phase I/II Study of Adjuvant Immunotherapy with Sentinel Lymph Node T Lymphocytes in Patients with Colorectal Cancer
10.1007/s00262-015-1715-3 · doi-reference
Lymphocytes in Tumor‐Draining Lymph Nodes Co‐Cultured with Autologous Tumor Cells for Adoptive Cell Therapy
10.1186/s12967-022-03444-1 · doi-reference
Characteristics of Successful Expansion of Tumor‐Infiltrating Lymphocytes from Colorectal Cancer Liver Metastasis
10.1038/s41598-025-85892-5 · doi-reference
Tumor‐Infiltrating Lymphocytes in Colorectal Cancer: the Fundamental Indication and Application on Immunotherapy
10.3389/fimmu.2021.808964 · doi-reference
Preventing Postsurgical Colorectal Cancer Relapse: a Hemostatic Hydrogel Loaded with METTL3 Inhibitor for CAR‐NK Cell Therapy
10.1016/j.bioactmat.2024.10.015 · doi-reference
Adoptive Transfer of NKG2D CAR mRNA‐Engineered Natural Killer Cells in Colorectal Cancer Patients
10.1016/j.ymthe.2019.03.011 · doi-reference
Enhancing the Physiological Characteristics of Chimeric Antigen Receptor Natural Killer Cells by Synthetic Biology
10.3389/fimmu.2025.1592121 · doi-reference
Critical Care Management of Chimeric Antigen Receptor T Cell‐Related Toxicity Be Aware and Prepared
10.1164/rccm.201810-1945ed · doi-reference
Current Advances and Challenges in CAR T‐Cell Therapy for Solid Tumors: Tumor‐Associated Antigens and the Tumor Microenvironment
10.1186/s40164-023-00373-7 · doi-reference
Bispecific Anti‐CD20, Anti‐CD19 CAR T Cells for Relapsed B Cell Malignancies: A Phase 1 Dose Escalation and Expansion Trial
10.1038/s41591-020-1081-3 · doi-reference
Integrating Spatial and Single‐Cell Transcriptomics Reveals Tumor Heterogeneity and Intercellular Networks in Colorectal Cancer
10.1038/s41419-024-06598-6 · doi-reference
Interleukin‐15‐Armoured GPC3 CAR T Cells for Patients with Solid Cancers
10.1038/s41586-024-08261-8 · doi-reference
Liver Metastasis Restrains Immunotherapy Efficacy via Macrophage‐mediated T Cell Elimination
10.1038/s41591-020-1131-x · doi-reference
Phase I Study of GUCY2C CAR‐T Therapy IM96 in Patients with Metastatic Colorectal Cancer
10.1200/jco.2024.42.16_suppl.2518 · doi-reference
